NeoFipronis® continues to expand its international reach as demand grows for regulated veterinary antiviral treatments for feline infectious peritonitis (FIP). The company today announced that its services are currently available to customers in several major global markets.

At present, NeoFipronis provides service to the following countries and regions:

United States, Canada, Australia, United Kingdom, France, Germany, Italy, Spain, Japan, and South Korea.

This expansion reflects the increasing global awareness of feline infectious peritonitis and the need for reliable antiviral treatment options for cats diagnosed with the disease.

Supporting Global Access to FIP Treatment

NeoFipronis® (Pronidesivir) is an oral antiviral tablet containing GS-441524, developed for the treatment of feline infectious peritonitis in cats. The product is designed to support practical veterinary use and improve treatment accessibility for pet owners and veterinary professionals.

With growing international interest in antiviral therapies targeting feline coronavirus, NeoFipronis aims to provide responsible access to regulated veterinary medicine through compliant distribution channels.

Commitment to Quality and Compliance

As global demand increases, NeoFipronis continues to focus on quality control, regulatory compliance, and product verification to ensure authenticity and safety.

Customers are encouraged to verify product authenticity and purchase through official or authorized channels to ensure reliable support and traceability.

Looking Ahead

The company plans to further expand its service coverage as regulatory conditions and regional availability allow. NeoFipronis remains committed to supporting veterinarians and cat owners worldwide by improving access to safe and reliable antiviral treatment options for feline infectious peritonitis.

For more information about availability in your region, customers can visit the official website or contact the NeoFipronis support team.